The Obama administration is transfering $81 million from other departments of health into funding Zika studies.
Sarepta announces the first patient has been dosed in their most recent Phase 3 clinical trial of assessing SRP-4045 and SRP-4053 for Duchenne muscular dystrophy.
The FDA has approved Vertex Pharmaceuticals’ Orkambi for use in children ages 6-11 years old with cystic fibrosis (CF) who have 2 copies of the F508del mutation.
This week, sarepta stock, number of daughters dying of cancer, football touchdowns, cost of CHOPS new program, and viewings of the #zebradanceoff
A quadriplegic cerebral palsy patient scored a touchdown in his town's biggest rivalry game.
Lale Welsh, executive director of the Neuromuscular Disease Foundation talks about the organization's recent patient conference, the news of data being shared between government, academic, pharmaceutical, and advocacy groups, as well the start of a gene therapy program,
Santhera Pharmaceuticals initiated their patient enrollment for their Phase 3 clinical trial of Raxone, testing respiratory function in Duchenne Muscular Dystrophy.
3 cases of the mumps have been confirmed at the University of Maryland
Janssen Research & Development has submitted a supplemental New Drug Application to the FDA for Imbruvica (Ibrutinib), a potential treatment of marginal zone lymphoma (MZL).
Amgen's Phase 3 multiple myeloma study did not meet its primary endpoint